Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) possess high mortality and morbidity across the globe. In India, BBV-152 (Covaxin^TM) and ChAdOx1-nCOV (Covishield^TM) vaccines are now being used to limit the spread of SARS-CoV-2 Infection. A Cross sectional observational study was designed to analyze the Antibody immune response to SARS CoV-2 vaccine quantitatively among Health Care Workers and it was correlated with age, sex, other comorbidities and blood group. A total of 160 fully vaccinated HCWs, the Anti-SARS-CoV-2 level was estimated by using Chemiluminescence Immuno Assay. A protective immune response following the complete course of the SARS-CoV-2 vaccine should be ≥ 1.00 S/C. A total of 160 HCWs (82 Male, 78 Female) who had completed both the doses of Covishield (n=128) and Covaxin (n=32). Both the vaccine recipient had mild to moderate symptoms and none of the HCWs had severe adverse events after administration of vaccine. Out of which, 143 (89.3%) HCWs showed seropositive and 17 (10.7%) HCWs showed seronegative. There was no notable variation in sex and other co-morbidities. Significantly, reduced antibody titers towards SARS-CoV-2 vaccine was noted among individuals aged ≤ 60 years and O+ve Blood group. Both the vaccines obtained successful immune response after their complete course, even though there was a significantly higher seropositivity rate in Covishield in spite of Covaxin recipients. Further, genomic correlative advanced studies can conclude the significance of non-responsiveness to SARS-CoV-2 vaccines among the HCWs.